Interferon beta-1a Articles
US FDA approves Merck KGaA's Rebif Rebidose
4 January 2013
US neurologists' adoption of STRATIFY JCV has shifted Tysabri earlier in the treatment of some MS patients
15 August 2012
Expanded use for Merck Serono’s Rebif in EU
25 January 2012
Recent Gilenya growth appears to be coming from initial trial among late adopters not expanded use among existing prescribers
30 November 2011
Genzyme’s MS drug Lemtrada shows significant efficacy versus Rebif
15 November 2011
Merck KGaA US units agree $44.3 million settlement with DoJ; Ranbaxy faces up to $1 billion fine?
5 May 2011
Nomura ups sales forecast for Novartis’s new oral MS drug Gilenya to $3.5 billion, as Biogen Idec says it is still confident about non oral products
24 September 2010
Uptake of the first oral MS therapies will result in the market value peaking at $8.4 billion in 2013
1 February 2010
Promising results for Novartis and Merck KGaA oral MS drug trials represent "shifting tide"
22 January 2010
Biogen Idec’s Tysabri surpasses $1 billion in 2009 sales; fampridine filed in EU, Canada; development deal with Trillium
13 January 2010
Does the MS market need another Interferon? US neurologists provide insight on the launch of Novartis’ Extavia
12 January 2010
UK Department of Health’s “money back” deal for MS drugs questioned; failing people with the disease
3 December 2009
US mid-caps Biogen, Forest and Gilead post in-line or better-than-expected three-month results
21 October 2009
Good news for Novartis’s MS drug fingolimod
1 October 2009
Merck KGaA's 1st-qtr profit tumbles 76.3% to 56.7M euros on lower liquid crystal sales
27 April 2009
Biogen's 1st-qtr profit jumps 54% to $244M
20 April 2009
Biopartners to appeal CHMP's Biferenox dismissal
2 March 2009
Biogen Idec's full-year 2008 sales jump 33%
16 February 2009
Stock Commentary - New York week to Jan 19, 2009
26 January 2009
Novartis MS drug: less relapse than Avonex
22 December 2008
Biogen's 3rd-qtr EPS up 71% on drug sales
3 November 2008
Promising Ph II data for Genzyme/Bayer's alemtuzumab
27 October 2008
Merck KGaA Rebif trial meets endpoint
29 September 2008
Biogen's 2nd-qtr 2008 revenue up 28%
4 August 2008
Teva's laquinimod enters Ph III study
21 July 2008
Stock Commentary - New York week to July 7, 2008
14 July 2008
Biogen Idec's 1st-qtr 2008 profit jumps 23%
5 May 2008
New Rebif formulation launched in UK
10 March 2008
Biogen's 4th-qtr net income climbs 85%
14 February 2008
Stock Commentary - New York week to Feb 4, 2008
11 February 2008
Stock Commentary - New York week to Jan 7, 2008
14 January 2008
Biogen ups 2007 income guide, on sales gains
14 January 2008
Stock Commentary - New York week to January 7, 2008
7 January 2008
Betaseron linked to fewer injection site reactions
12 November 2007
Stock Commentary - New York week to Oct 29, 2007
5 November 2007
Merck KGaA's net falls but beats forecasts
29 October 2007
Stock Commentary - New York - week to October 15, 2007
22 October 2007
Alemtuzumab cuts relapse risk in RRMS
22 October 2007
Merck KGaA
15 October 2007
Genzyme/Bayer start Ph III alemtuzumab program
1 October 2007
Biogen forecasts 2007 sales growth of 16-18%, and EPS to increase 20% a year to 2010
17 September 2007
Biferonex MAA submitted to EMEA
3 September 2007
Tysabri improves MS sufferers' QOL
3 September 2007
Serono buy hits Merck KGaA 2nd-qtr profits, but still beats consensus, and sales leap 52%
30 July 2007
Biogen Idec share repurchase plan
4 June 2007
Strong Ph II data on Genzyme/Bayer's MS drug
14 May 2007
Biogen's 1st-qtr income climbs 7% to $131M
14 May 2007
Stock Commentary - New York week to April 23, 2007
30 April 2007
Merck KGaA attributes 1st-qtr loss to Serono buy
30 April 2007
Biogen's Avonex: most cost-effective INF-beta
23 April 2007
Bayer and Novartis in MS drug deal
2 April 2007
Biogen Idec's 4th-qtr profit up 95% to $109M
26 February 2007
Merck Serono initiates Ph II trial of cladribine
29 January 2007
Merck Serono SA officially launched
15 January 2007
Serono initiates Ph III Rebif trial
18 December 2006
Biogen Idec's Avonex launched in Japan
20 November 2006
Stock Commentary - New York week to Nov 6, 2006
13 November 2006
Biogen Idec's 3rd-qtr income rockets 476%
13 November 2006
Serono's 3rd-qtr 2006 sales rise 8.4% on Rebif
30 October 2006
New form of Serono's Rebif shows promise
9 October 2006
Superior adherence with BI's Avonex
9 October 2006
MS patients on Teva's Copaxone miss less working days
18 September 2006
13 new drugs added to Japan's NHI list
18 September 2006
Teva's Azilect approved for early PD in Canada
28 August 2006
Serono's net income up 8% in 2nd-qtr
31 July 2006
Takeover costs impact Schering AG's 1st-half 2006
31 July 2006
Takeover costs impact Schering's 1st-half 2006
26 July 2006
EC approves Rebif indication revision
17 July 2006
Serono reprimanded on ABPI Code breach
26 June 2006
Teva's Copaxone: "less relapses than Avonex"
12 June 2006
BI's 1st-qtr revenues hit $611M, up 4%
8 May 2006
Elan's Tysabri viewed positively by CHMP
8 May 2006
Strong Ph II data for Novartis' FTY720
10 April 2006
Serono submits Rebif sBLA to US FDA
10 April 2006
Strong relapse data for Biogen Idec's Avonex
10 April 2006
Strong relapse data for Biogen Idec's Avonex
10 April 2006
Stock Commentary - Europe - week to Mar 13, 2006
20 March 2006
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
